Formation of a High Affinity Lipid-Binding Intermediate during the Early Aggregation Phase of α-Synuclein
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The alpha-synuclein (alpha-syn) protein is clearly implicated in Parkinson's disease (PD). Mutations or triplication of the alpha-syn gene leads to early onset PD, possibly by accelerating alpha-syn oligomerization. alpha-syn interacts with lipids, and this membrane binding activity may relate to its toxic activity. To understand how the alpha-syn aggregation state affects its lipid binding activity we used surface plasmon resonance to study the interaction of wild-type and mutant alpha-syn with a charged phospholipid membrane, as a function of its aggregation state. Apparent dissociation constants for alpha-syn indicated that an intermediate species, present during the lag phase of amyloid formation, binds with an increased affinity to the membrane surface. Formation of this species was dependent upon the rate of fibril formation. Fluorescence anisotropy studies indicate that only upon the formation of amyloid material can alpha-syn perturb the acyl-chain region of the lipid bilayer. Circular dichroism spectroscopy showed that upon aging, both wild-type and mutant alpha-syn lose their ability to form lipid-bound alpha-helical species once they become fibrillar. These results indicate that alpha-syn forms a high affinity lipid binding intermediate species during fibril formation. Oligomeric alpha-syn is known to be toxic, and it is feasible that the high affinity binding species described here may correspond to a toxic species involved in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, B., Koh, Y. H., Beckstead, R. B., Budnik, V., Ganetzky, B., & Bellen, H. J. (1998) · Neuron · doi:10.1016/s0896-6273(00)80664-9 · Cited by 434
Research works printed but not linked: 57
- Dauer W., 2003, Neuron 39, 889−909.
- Eliezer D., 2001, J. Mol. Biol., 307, 10.1006/jmbi.2001.4538 · DOI · Paper page
- Davidson W. S., 1998, J. Biol. Chem., 273, 10.1074/jbc.273.16.9443 · DOI · Paper page
- Uversky V. N., 2001, J. Biol. Chem., 276
- Weinreb P. H., 1996, Biochemistry 35, 13709−13715.
- Der-Sarkissian A., 2003, J. Biol. Chem., 278, 10.1074/jbc.M305266200 · DOI · Paper page
- Wood S. J., 1999, J. Biol. Chem., 274
- Morris H. R., 2005, Ann. Med., 37, 96, 10.1080/07853890510007269 · DOI
- Conway K. A., 2000, Ann. N. Y. Acad. Sci., 920, 45, 10.1111/j.1749-6632.2000.tb06903.x · DOI · Paper page
- Conway, K. A., Harper, J. D., and Lansbury, P. T., Jr. (2000) Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid,Biochemistry. 39, 2552−25563. · DOI · Paper page
- Greenbaum E. A., 2005, J. Biol. Chem., 280
- Conway, K. A., Harper, J. D., and Lansbury, P. T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease,Nat. Med.4, 1318−13120. · DOI · Paper page
- Tabrizi S. J., 2000, Hum. Mol. Genet. 9, 2683−2689.
- Narhi L., 1999, J. Biol. Chem., 274, 10.1074/jbc.274.14.9843 · DOI · Paper page
- Conway K. A., 2000, Proc. Natl. Acad. Sci. U.S.A. 97, 571−576.
- Bussell R., Jr., 2004, Biochemistry 43, 4810−4818.
- Jo E., 2002, J. Mol. Biol., 315
- Chandra S., 2003, J. Biol. Chem., 278
- Perrin R. J., 2000, J. Biol. Chem., 275, 10.1074/jbc.M004851200 · DOI · Paper page
- Dixon C., 2005, Genetics, 170, 59, 10.1534/genetics.104.035493 · DOI · Paper page
- Jensen P. H., 1998, J. Biol. Chem., 273
- Fortin D. L., 2004, J. Neurosci., 24, 10.1523/JNEUROSCI.1594-04.2004 · DOI · Paper page
- Zhu M., 2003, J. Biol. Chem., 278
- Cole N. B., 2002, J. Biol. Chem., 277
- Cappai R., 2005, FASEB J., 19, 10.1096/fj.04-3437fje · DOI · Paper page
- Whitmore L., 2004, Nucleic Acids Res. 32, W668−W673.
- Lobley A., 2002, Bioinformatics 18, 211−212.
- Smith D. P., 2001, Protein Sci. 10, 1775−1784.
- Conway, K. A., Harper, J. D., and Lansbury, P. T., Jr. (2000) Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid,Biochemistry 39, 2552−2563. · DOI · Paper page
- Smith A. M., 2006, J. Mol. Biol., 364, 19, 10.1016/j.jmb.2006.08.081 · DOI
- Li J., 2001, Biochemistry. 40, 11604−11613.
- Kubo S., 2005, J. Biol. Chem., 280, 10.1074/jbc.M504894200 · DOI · Paper page
- Jo E., 2000, J. Biol. Chem., 275
- Narayanan V., 2001, Biochemistry 40, 9927−9934.
- Rhoades E., 2006, Biophys. J., 90, 10.1529/biophysj.105.079251 · DOI · Paper page
- Ramakrishnan M., 2006, Biochemistry 45, 3386−3395.
- Dahlquist F. W., 1978, Methods Enzymol. 48, 270−299.
- Roy M. O., 2001, J. Mol. Recognit., 14, 78
- Zhu M., 2003, J. Biol. Chem., 278
- Müller W. E., 2001, Biochem. Soc. Trans., 29, 10.1042/bst0290617 · DOI · Paper page
- Kamp F., 2006, J. Biol. Chem., 281, 10.1074/jbc.M512292200 · DOI
- Li J., 2001, Biochemistry 40, 11604−11613.
- Lashuel H. A., 2002, J. Mol. Biol., 322, 10.1016/S0022-2836(02)00735-0 · DOI · Paper page
- Volles M. J., 2001, Biochemistry 40, 7812−7819.
- Sharon R., 2001, Proc. Natl. Acad. Sci. U.S.A. 98
- Zhang B., 1998, Neuron 21, 1465−1475.
- Lucke C., 2006, J. Lipid Res., 47
- Volles M. J., 2002, Biochemistry 41, 4595−4602.
- Hou X., 2005, Biochemistry 44, 11618−11627.
- Kaylor J., 2005, J. Mol. Biol., 353, 10.1016/j.jmb.2005.08.046 · DOI · Paper page
- Dusa A., 2006, J. Am. Chem. Soc., 48
- Krishnan S., 2003, Biochemistry 42, 829−837.
- Kayed R., 2004, J. Biol. Chem., 279, 10.1074/jbc.C400260200 · DOI · Paper page
- Volles M. J., 2007, J. Mol. Biol., 366, 10.1016/j.jmb.2006.12.044 · DOI · Paper page
- Rochet J. C., 2004, J. Mol. Neurosci., 23, 34, 10.1385/JMN:23:1-2:023 · DOI · Paper page
- Sharma N., 2006, J. Mol. Neurosci., 28, 10.1385/JMN:28:2:161 · DOI
- Abbreviations DPH, diphenyl-1,3,5-hexatriene
Cited by
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation
Bartels, T., Choi, J. G., & Selkoe, D. J. (2011) · Nature · doi:10.1038/nature10324 · Cited by 1,263
Amyloidogenic Protein–Membrane Interactions: Mechanistic Insight from Model Systems
Butterfield, S. M., & Lashuel, H. A. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200906670 · Cited by 592
Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases
Irvine, G. B., El-Agnaf, O. M., Shankar, G. M., & Walsh, D. M. (2008) · Molecular Medicine · doi:10.2119/2007-00100.irvine · Cited by 550
Jao, C. C., Hegde, B. G., Chen, J., Haworth, I. S., & Langen, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807826105 · Cited by 497
Implications of peptide assemblies in amyloid diseases
Ke, P. C., Sani, M.-A., Ding, F., Kakinen, A., Javed, I., Separovic, F., Davis, T. P., & Mezzenga, R. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00372b · Cited by 338
Metadata
- Authors
- Smith, D. P., Tew, D. J., Hill, A. F., Bottomley, S. P., Masters, C. L., Barnham, K. J., & Cappai, R.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-01-08
- Volume
- 47
- Issue
- 5
- Pages
- 1425-1434
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W1991335320
- Cited by
- 66
- References
- 1
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.